WAYNE, Pa., Feb. 28, 2018 -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company focused on identifying, developing, and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology, will report financial results for the fourth quarter and year ending December 31, 2017 on Monday, March 12, 2018, before the U.S. financial markets open.
Management will provide an update on the Company and discuss fourth quarter and year-end 2017 results as well as expectations for the future via conference call on Monday, March 12, 2018, at 8:00 AM ET. To participate on the live call, please dial (844) 776-7782 (domestic) or (661) 378-9535 (international), and reference conference ID 1495576 prior to the start of the call.
A live webcast of the event can be accessed on the Events and Presentations page on the Investors section of the Aclaris website at http://www.aclaristx.com/events-and-webcasts. A replay of the webcast will be archived on the Aclaris website following the event.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a dermatologist-led biopharmaceutical company committed to identifying, developing and commercializing innovative therapies to address significant unmet needs in aesthetic and medical dermatology and immunodermatology. The Company is focused on market segments with no FDA-approved medications or where treatment gaps exist. Aclaris is based in Wayne, Pennsylvania and more information about the company can be found by visiting the Aclaris website at www.aclaristx.com.
Contact:
Aclaris Contact
Michael Tung, M.D.
Senior Vice President / Corporate Strategy / Investor Relations
484-329-2140
[email protected]
Media Contact
Laura Morgan
TogoRun
347-342-8496
[email protected]


Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings
DeepSeek to Raise AI API Prices as Demand for New Models Surges
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 



